Relapsed or Refractory T-cell lymphoma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 T-cell lymphomas are a heterogeneous group of uncommon non-Hodgkin’s lymphomas (NHLs), accounting for approximately 10–15% of all NHLs. The prognosis for patients with PTCL, from historical retrospective studies, is generally poor, with a treatment course characterized by multiple relapses and initial refractory disease. Patients with relapsed disease are usually treated with combination chemotherapy such as ICE (ifosfamide, carboplatin, and etoposide) if stem cell transplantation is contemplated as the next step in therapy. However, some regimens or transplants might not suit everyone because of their high toxicity levels. Less toxic single-agent treatments are also available and might induce a long-lasting remission in such patients. These therapies include belinostat (Beleodaq), brentuximab vedotin (Adcetris), pralatrexate (Folotyn), and romidepsin (Istodax). These drugs are approved by the U.S. Food and Drug Administration (FDA) for patients who have relapsed or those who have not responded to their first line of chemotherapy.

 

The competitive landscape of Relapsed or Refractory T-cell lymphoma includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Relapsed or Refractory T-cell lymphoma across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory T-cell lymphoma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Relapsed or Refractory T-cell lymphoma – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          ASTX660          Otsuka Pharmaceutical Co., Ltd.            Phase 2

2          Tenalisib and Romidepsin          Rhizen Pharmaceuticals SA            Phase 2

3          Mogamulizumab            Kyowa Kirin, Inc.           Phase 2

4          Panobinostat     Novartis            Phase 2

5          Fostamatinib Disodium  Rigel Pharmaceuticals   Phase 2

6          Tislelizumab      BeiGene           Phase 2

7          Tipifarnib           Kura Oncology, Inc.       Phase 2

8          Valemetostat Tosylate   Daiichi Sankyo Co., Ltd. Phase 2

9          AZD4573          AstraZeneca     Phase 2

10        GB226  Genor Biopharma Co., Ltd.        Phase 2

Continued